Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Kedudukan dalam Saham #2182
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Harga Saham
$114.07
Modal Pasaran
$9.38B
Perubahan (1 hari)
5.55%
Perubahan (1 tahun)
88.55%
Negara
US
Perdagangan Kymera Therapeutics, Inc. (KYMR)

Kategori

Healthcare
Nisbah P/B bagi Kymera Therapeutics, Inc. (KYMR)
Nisbah P/B pada October 2026 TTM: 6.95
Menurut laporan kewangan dan harga saham terkini Kymera Therapeutics, Inc., nisbah P/B semasa (TTM) ialah 6.95. Pada akhir 2023, nisbah P/B syarikat ialah 3.76.
Sejarah nisbah P/B untuk Kymera Therapeutics, Inc. dari 2018 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
2026 (TTM) 6.95 92.50%
2024 3.61 -3.97%
2023 3.76 36.99%
2022 2.75 -58.57%
2021 6.63 -31.88%
2020 9.73 -148.89%
2019 -19.91 -53.72%
2018 -43.01 0.00%
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
6.251 -10.05%
US
13.2547 90.73%
US
4.208 -39.45%
AU
- -
CH
6.1824 -11.04%
NL